CYduct Diagnostics Inc (CYDX)

[Aqua]

Honestly, let's not substitute opinions for the facts. Solos markets about 200 products in the endoscopic market that are FDA-approved and later CE Mark approved. It's all about adding value to the company in the long-term. To say that Solos is in the business to reverse split and dilute its stock should know that companies that do engage in such practices usually do not stay in business too long. In Solos case, its strategic initiative was to achieve both the FDA approvals and CE Mark to gain a competitive advantage in the EU and Canada and Asia and other developing markets to expand its revenue growth to carve a market niche. Cheers!